孕三烯酮+米非司酮治疗子宫内膜异位症合并不孕的效果和安全性分析

目的分析孕三烯酮+米非司酮治疗子宫内膜异位症合并不孕的效果和安全性。方法研究对象为就诊于我院的104例子宫内膜异位症合并不孕患者,研究时间2017年1月至2019年3月。采用数字随机分组方法,将患者分成治疗组和对照组,将孕三烯酮单独用于对照组,治疗组应用孕三烯酮、米非司酮联合治疗。观察两组临床疗效、各项临床指标变化、受孕率和不良反应。结果治疗组患者在治疗后的孕酮、雌二醇、黄体生成素等指标水平均优于对照组;治疗组患者在治疗后的子宫内膜厚度低于对照组;治疗组患者治疗后的子宫内膜厚度低于对照组,差异有统计学意义(P0.05)。治疗组获得的临床总有效率高于对照组,差异有统计学意义(P0.05)。随访期间治疗组患者受孕率高于对照组,差异有统计学意义(P0.05)。患者受孕率更高。两组患者对比用药不良反应发生率比较,差异无统计学意义(P0.05)。结论子宫内膜异位症合并不孕,临床药物应用(孕三烯酮+米非司酮)治疗,治疗效果显著提高,受孕率增加;且治疗期间无严重不良反应,用药安全性高。

Analysis of the effect and safety of gestrinone+mifepristone in the treatment of endometriosis with infertility

Objective To analyze the efficacy and safety of gestrinone+mifepristone in the treatment of endometriosis with infertility.Methods 104 patients with endometriosis and infertility who were admitted to our hospital from January 2017 to March 2019 were selected as the subjects of the study.The patients were divided into the treatment group and the control group using a digital randomization method.The control group was treated with gestrinone alone,and the treatment group was treated with gestrinone and mifepristone.The clinical efficacy,changes in various clinical indicators,pregnancy rate,and adverse reactions in the two groups were observed.Results the levels of progesterone,estradiol,and luteinizing hormone in the treatment group were better than those in the control group after treatment.The endometrial thickness of the treatment group after treatment was lower than that of the control group.The endometrial thickness of the treatment group was lower than that of the control group after treatment,and the difference between the groups was significant (P<0.05).The total clinical effective rate obtained in the treatment group was higher than that in the control group,and the difference between the groups was significant (P<0.05).During the follow-up period,the treatment group''s pregnancy rate was higher than that in the control group,and the difference between the groups was significant(P<0.05).The pregnancy rate of the treatment group was higher.There was no statistical difference in the incidence of adverse drug reactions between the two groups (P>0.05).Conclusion Clinical drug application (gestrinone+mifepristone) significantly improves the effect in treating endometriosis with infertility and increases the pregnancy rate.